Endothelial Regulation of Vascular Tone and Growth by Lüscher, Thomas F. & Tanner, Felix C.
AJH 1993; 6:283S-293S 
Endothelial Regulation of Vascular Tone 
and Growth 
Thomas F. Luscher and Felix C. Tanner 
The endothelium regulates vascular tone by releas-
ing factors involved in relaxation and contraction, in 
coagulation and thrombus formation, and in growth 
inhibition and stimulation. Endothelium-depend-
ent relaxations are elicited by transmitters, 
hormones, platelet substances, and the coagulation 
system, and by physical stimuli such as the shear 
stress from circulating blood. They are mediated by 
the endothelium-derived relaxing factor, recently 
identified as nitric oxide, which causes vasodilation 
and platelet deactivation. Other proposed endothe-
lium-derived relaxing factors include a hyperpolar-
izing factor, lipooxygenase products, and the cyto-
chrome P450 pathway. Endothelium-derived con-
tracting factors are produced by the cyclooxygenase 
pathway and by endothelial cells, which produce 
the peptide endothelin-1, a potent vasoconstrictor 
that under normal conditions circulates at low lev-
els. The endothelium produces both growth inhib-
itors—normally dominant—and growth stimuli. 
Denuded or dysfunctional endothelium leads to a 
proliferative response and intimal hyperplasia in 
the vessel wall; moreover, platelets adhere to the 
site and release potent growth factors. Endothelial 
dysfunction has numerous causes: Aging is associ-
ated with increased formation of contracting factor 
and decreased relaxing factor; denudation, such as 
by coronary angioplasty, impairs the capacities of 
regenerated endothelial cells; oxidized low-density 
lipoproteins and hypercholesterolemia interfere 
with nitric oxide production; hypertension morpho-
logically and functionally alters the endothelium; 
and atherosclerosis markedly attenuates some endo-
thelium-dependent relaxations. For patients with 
coronary bypass grafts, differences in endothelium-
derived vasoactive factors between the internal 
mammary artery and the saphenous vein may be im-
portant determinants of graft function, with the 
mammary artery having more pronounced relaxa-
tions than the saphenous vein and thus a higher pat-
ency rate. Am J Hypertens 1993;6:283S-293S 
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The endothelium takes part in the regulation of vascular tone 1 by releasing relaxing and con-tracting factors both under basal conditions and when activated by neurotransmitters, 
hormones, autacoids, or physical stimuli. In addition, 
endothelial cells release factors involved in coagula-
tion and thrombus formation and in growth inhibition 
and stimulation. 
Owing to its strategic anatomic position, the endothe-
lium is a target organ for hypertension, diabetes, and 
hyperlipidemia.1 Alterations in endothelial function 
may contribute to the pathogenesis as well as to the pro-
gression and complications of hypertension and its se-
quelae such as atherosclerotic vascular disease. 
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FIGURE 1. The L-Arginine pathway in the blood vessel wall: 
Endothelial cells form nitric oxide (NO) from L-arginine by the ac­
tivity of the constitutive nitric oxide synthase (NOsc), which can be 
inhibited by analogs of the amino acid such as L-NG-monomethyl 
arginine (L-NMMA). Nitric oxide activates soluble guanylyl 
cyclase (sGC) in vascular smooth muscle and platelets and causes 
increases in cyclic 3/,5/-guanosine monophosphate (cGMP), which 
mediates relaxation and platelet inhibition, respectively. Shear 
stress and receptor-operated agonists (not shown) stimulate the re­
lease of nitric oxide. In addition, vascular smooth muscle cells can 
form nitric oxide by the activity of an inducible (by tumor necrosis 
factor, interleukin 1, and lipopolysaccharide) form of nitric oxide 
synthase (NOSt). 
ENDOTHELIUM-DEPENDENT REGULATION 
OF VASCULAR TONE 
Relaxing Factors Endothelium-dependent relaxa­
tions occur both in vitro and in vivo 2 ^; transmitters, 
hormones, substances derived from platelets, and the 
coagulation system can cause these responses.1 Fur­
thermore, physical stimuli, such as shear stress (ex­
erted by the circulating blood), elicit endothelium-de­
pendent vasodilation.5 
Endothelium-derived Nitric Oxide The relaxations 
are mediated by a diffusible substance with a half-life 
of a few seconds,6 the so-called endothelium-derived 
relaxing factor (EDRF), 2 which has recently been iden­
tified as nitric oxide. 7 Endothelium-derived nitric 
oxide (EDNO) has the same chemical characteristics as 
EDRF and is liberated in amounts sufficient to account 
for the vascular action of EDRF. 7 Possibly, EDNO is 
not released as a free radical, but rather as a nitrosyl-
ated compound, for instance, S-nitrosocysteine.8 
EDNO is formed from L-arginine by oxidation of the 
guanidine-nitrogen terminal of L-arginine (Figure 
l). 9Nitric oxide synthase has been cloned recently 1 0; it 
is primarily a cytosolic enzyme requiring calmodulin, 
calcium, and NADPH, and has similarities to cyto­
chrome P450 enzymes. 1 0 , 1 1 Several isoforms of the en­
zyme occur not only in endothelial cells, but also in 
platelets, macrophages, vascular smooth muscle cells, 
and in the brain . 1 2 - 1 5 Endothelium-dependent relaxa­
tions to serotonin are inhibited by analogs of L-argin­
ine such as L-AP-monomethyl arginine (L-NMMA) 
and are restored by L-arginine, but not by D-argin-
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FIGURE 2. Endothelium-dependent effects to the inhibitor of nitric oxide formation i-NG-monomethyl arginine (L-NMMA) in the 
human internal mammary artery. In the preparation with endothelium, L-NMMA causes concentration-dependent contractions and 
augments those to norepinephrine. In contrast, in the preparation without endothelium, L-NMMA has no effect. From Yang et al3 with 
permission. 
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FIGURE 3. Effect of L-NG-monom-
ethyl arginine (L-NMMA), methylene 
blue, and hemoglobin on endothelium-
dependent relaxations to bradykinin in 
epicardial coronary arteries. L-NMMA 
and methylene blue only cause a weak 
shift of the concentration-response 
curve to higher concentrations of the re­
laxing agonist, whereas hemoglobin also 
reduces the maximal relaxation to 
bradykinin. From Richard et al16 with 
permission. 
ine. 3 ' 1 6 In quiescent arteries, L-NMMA causes endothe­
lium-dependent contractions (Figure 2) . 3 When in­
fused in rabbits, it causes long-lasting increases in 
blood pressure that are reversible by L-arginine,1 7 de­
monstrating that the vasculature is in a constant state 
of vasodilation as a result of the continuous release of 
nitric oxide from the endothelium. 
Relaxations to EDNO are associated with an in­
crease in cyclic 3',5'-guanosine monophosphate 
(cGMP) in vascular smooth muscle cells (Figure l ) . 1 8 
Methylene blue, an inhibitor of soluble guanylyl 
cyclase, prevents the production of cGMP and inhibits 
endothelium-dependent relaxations, 1' 1 8 an indication 
that EDNO causes relaxations by stimulating the en­
zyme and, in turn, the formation of cGMP. Soluble 
guanylyl cyclase is also present in platelets and is acti­
vated by EDNO (Figure l ) . 1 9 Increased levels of cGMP 
in platelets are associated with reduced adhesion and 
aggregation. Because EDNO causes both vasodilata­
tion and platelet deactivation, it represents an impor­
tant antithrombotic feature of the endothelium. 
Vascular Smooth Muscle-derived Nitric Oxide Al­
though the media of the blood vessel wall normally 
does not produce nitric oxide, vascular smooth muscle 
cells (including those obtained from human vessels) 
can do so when stimulated by endotoxin and inter-
leukin-1 (Figure l ) . 2 0 - 2 3 Thus, it appears that there are 
at least two enzymes for the production of nitric oxide: 
The constitutive endothelial enzyme is calcium de­
pendent and produces picomoles of nitric oxide, 
whereas the inducible enzyme is calcium independent, 
produces nanomoles of nitric oxide, and is primarily 
expressed in smooth muscle cells and monocytes. Acti­
vation of the L-arginine pathway in smooth muscle 
cells by endotoxin, interleukin-1, and tumor necrosis 
factor may play a role in septic shock and explain why 
the cardiovascular system becomes resistant to cat­
echolamines under these conditions. On the other 
hand, L-NMMA may provide a therapeutic tool as it 
can prevent nitric oxide formation in vascular smooth 
muscle cells stimulated with endotoxin; preliminary 
data indeed suggest that L-NMMA may be beneficial 
for patients in septic shock. 2 4 
Prostacyclin Prostacyclin increases cyclic 3',5'-ade-
nosine monophosphate (cAMP) in smooth muscle and 
in platelets and, thus, causes relaxation and inhibition 
of platelet aggregation. 1' 2 5 However, the contribution 
of prostacyclin to endothelium-dependent relaxations 
is negligible.1 In human platelets, EDNO and prostacy­
clin synergistically inhibit aggregation. 2 6 
Other Endothelium-derived Relaxing Factors In the 
porcine coronary circulation, L-NMMA inhibits endo­
thelium-dependent relaxations to serotonin, but not to 
bradykinin (Figure 3 ) . 1 6 As similar effects are obtained 
by other inhibitors of the action of EDNO, such as he­
moglobin and methylene blue, endothelial cells appear 
to release another relaxing factor distinct from nitric 
oxide. Prostacyclin can be excluded, as it is a weak vas­
odilator of porcine coronary arteries, and indometha­
cin does not affect the response to bradykinin. Several 
candidates for these responses have been proposed, 
including a hyperpolarizing factor, products of lipoox-
ygenase, or the cytochrome P450 pathway. 1 
Acetylcholine causes not only an endothelium-de­
pendent relaxation, but also an endothelium-depend­
ent hyperpolarization of vascular smooth muscle. 2 7 ' 2 8 
Although the relaxation to the muscarinic agonist is 
sustained, the hyperpolarization is transient. An endo-
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FIGURE 4. The endothelium is a source of 
different contracting factors. Products of cy­
clooxygenase, such as thromboxane A2 (TX 
A2) and prostaglandin H2 (PGH2) have a di­
rect contractile effect, while superoxide ani­
ons (02) induce increases in tension by inac­
tivating nitric oxide (NO). Endothelin (ET), 
as well as angiotensin II (A II), are also endo­
thelium-derived contracting factors, as they 
are both produced by endothelial cells. 
Smooth 
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thelium-dependent hyperpolarizing factor (EDHF) 
distinct from nitric oxide may be involved, although 
the latter was itself shown to have hyperpolarizing 
properties under certain conditions.2 7 , 2 9 The EDHF ap­
pears to activate ATP-sensitive potassium channels or 
sodium-potassium ATPase in smooth muscle, or 
both. 2 7 , 3 0 The hyperpolarization may contribute to en­
dothelium-dependent relaxations or reduce the sensi­
tivity of vascular smooth muscle to vasoconstrictor 
stimuli. 
Contracting Factors 
Cyclooxygenase-dependent Endothelium-derived Contract­
ing Factor (EDCF) Exogenous arachidonic acid 
evokes endothelium-dependent contractions that can 
be prevented by indomethacin (an inhibitor of cy­
clooxygenase).3 1 In the human saphenous vein, ace­
tylcholine and histamine evoke endothelium-depend­
ent contractions; in the presence of indomethacin, 
however, these relaxations are unmasked.3 The prod­
ucts of cyclooxygenase mediating the contractions are 
thromboxane A 2 in the case of acetylcholine and en-
doperoxides (prostaglandin H 2 ) in that of histamine 
(Figure 4 ) . 3 
The cyclooxygenase pathway is also a source of su­
peroxide anions, which can mediate endothelium-de­
pendent contractions either by the breakdown of nitric 
oxide or by direct effects on vascular smooth muscle 
(Figure 4 ) . 3 2 Thus, the cyclooxygenase pathway pro­
duces a variety of endothelium-derived contracting 
factors; their release appears to be more prominent in 
veins than in arteries.1 
Endothelin Endothelial cells produce the 21-
amino-acid peptide endothelin (Figure 4 ) . 1 , 3 3 Among 
the three peptides—endothelin-1, endothelin-2, and 
endothelin-3—endothelial cells appear to produce en­
dothelin-1 exclusively.1 
Translation of messenger RNA generates preproen-
dothelin, which is converted to big endothelin3 3; the 
formation of endothelin-1 by the endothelin-convert-
ing enzyme is then necessary for the development of 
full vascular activity.3 4 The expression of messenger 
RNA and the release of the peptide are stimulated by 
thrombin, transforming growth factor-β, interleukin-1, 
epinephrine, angiotensin II, arginine vasopressin, cal­
cium ionophore, and phorbol ester (Figure 4 ) . 1 , 3 3 , 3 5 
Endothelin-1 is a potent vasoconstrictor both in 
vitro and in vivo. In the coronary circulation and the 
human forearm circulation, endothelin-1 causes vaso­
dilation at lower concentrations and marked contrac­
tions at higher concentrations (Figure 5 ) . 3 6 , 3 7 In human 
arterial and venous coronary bypass vessels, it causes 
marked contractions.3 8 
The circulating levels of endothelin-1 are very low, 
however, suggesting that little of the peptide is formed 
under physiological conditions.3 9 This may be related 
Endothe l in ( n g / m i n / 1 0 0 m l ) 
FIGURE 5. Effects of endothelin on blood flow in the human fore­
arm circulation. low concentrations of endothelin (0.5 ng/min/100 
mL) cause a slight increase, whereas higher concentrations of the 
peptide (25 and 50 ng/min/100 mL) induce a marked decrease of 
forearm blood flow. Modified from Kiowski et al57 with permission. 
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FIGURE 6. Endothelium and vascular growth. 
The endothelium produces growth inhibitors such 
asheparin (HP), heparin sulphates (HS), trans­
forming growth factor beta (TGFB), and also ni­
tric oxide (EDNO). On the other hand, it releases 
growth promotors, such as platelet-derived 
growth factor (PDGF), thrombospondin (TS), and 
possibly endothelin (ET). At sites of damaged en­
dothelium the production of nitric oxide (EDNO) 
and prostacyclin (PGI2) is diminished, favoring 
platelet adhesion and aggregation. PDGF is re­
leased by aggregating platelets and leads to prolif­
eration as well as migration of vascular smooth 
muscle cells into the intima. The endothelium 
most probably takes part in these structural 
changes of the vascular wall, at least indirectly, by 
inhibiting platelet aggregation and with that the 
release of growth-stimulating factors. 
to the absence of stimuli or to the presence of potent 
inhibitory mechanisms, or to both, or it may be that the 
peptide is released preferentially toward vascular 
smooth muscle cells. 3 5 , 4 0 ' 4 1 Indeed, three inhibitory 
mechanisms regulating endothelin production have 
been delineated: 1) cGMP-dependent inhibition35; 2) 
cAMP-dependent inhibition42; and 3) an inhibitory fac­
tor produced by vascular smooth muscle cells. 4 3 The 
cGMP-dependent mechanism can be activated by 
EDNO, nitroglycerine, 3-morpholino sydnominine 
(SIN-1),4 4 and atrial natriuretic peptide (which acti­
vates particulate guanylyl cyclase). 4 5 Thus, after inhi­
bition of endothelial nitric oxide production, the 
thrombin-induced formation of endothelin is aug­
mented 3 5; on the other hand, SIN-1 prevents the 
thrombin-induced endothelin release by a cGMP-de-
pendent mechanism. 4 4 Endothelin can also release ni­
tric oxide and prostacyclin from endothelial cells in 
what may represent a negative feedback mechanism. 4 0 
The contraction to endothelin is not related to direct 
activation of voltage-operated calcium channels on vas­
cular smooth muscle, as calcium antagonists do not pre­
vent its effects in most blood vessels. 4 0 ' 4 6 , 4 7 However, 
the peptide activates indirectly those channels in the 
porcine coronary artery where calcium antagonists at­
tenuate endothelin-induced vasoconstriction.48 In the 
human forearm circulation, endothelin-1 induces po­
tent contractions, which can be prevented by nifedipine 
and verapamil hydrochloride, unmasking the vasodila­
tor effects of the peptide. 3 7 The vasodilator effects of en­
dothelin are related to the endothelial production of 
prostacyclin, whereas nitric oxide may contribute to the 
relaxation effects.49 Although endothelin is a secre-
tagogue for atrial natriuretic factor, its release is not in­
volved in the vasodilator action of endothelin.50 
EDNO also interacts with endothelin at the level of 
vascular smooth muscle. Indeed, the contractions to 
the peptide are enhanced after endothelial removal, in­
dicating that basal production of EDNO reduces the 
response to the peptide. 3 8 Stimulation of the formation 
of EDNO by acetylcholine reverses endothelin-in­
duced contractions in most blood vessels although this 
mechanism appears to be less potent in veins. 3 8 
ENDOTHELIAL REGULATION OF VASCULAR 
GROWTH 
Removal of the endothelium is a procedure that invari­
ably leads to a proliferative response in the blood ves­
sel wall with intimal hyperplasia. 5 1 Important growth 
inhibitors produced by the endothelium are heparin, 
heparin sulfates, transforming growth factor-β, and 
most likely nitric oxide. 5 2 , 5 3 On the other hand, endo­
thelial cells can also produce growth factors such as 
basic fibroblast growth factor, platelet-derived growth 
factor (PDGF), and possibly also endothelin (Figure 
6 ) . 5 4 , 5 5 These factors contribute to proliferative re­
sponses, at least under certain conditions, whereas it 
has to be assumed that under normal conditions inhib­
itory stimuli prevail. At sites of endothelial denuda­
tion or dysfunction, platelets adhere and release po­
tent growth factors such as PDGF. 5 6 Hence, the platelet 
inhibitory effect 1 9 of nitric oxide and prostacyclin also 
contribute indirectly to growth inhibition (Figure 6). 
In vascular smooth muscle cells from saphenous 
vein coronary bypass grafts exposed to pulsatile 
stretch, the [3H]thymidine incorporation is enhanced 
after 24 h of stretch, whereas the cell number is in­
creased after 6 days. In contrast, both [3H]thymidine 
incorporation and cell number remain constant in vas­
cular smooth muscle cells from internal mammary ar­
teries (Figure 7 ) . 5 7 Thus, the stimulation by pulsatile 
stretch of vascular smooth muscle cell proliferation in 
saphenous vein, but not in internal mammary artery, 
may contribute to the higher occlusion rate of venous 
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FIGURE 7. Proliferative responses to pulsatile stretch (60 cy-
cles/min) of human vascular smooth muscle cells from internal 
mammary artery and saphenous vein. After 24 h of pulsatile 
stretch the [3H]thymidine incorporation (top) was increased in sa-
phenous vein but not in mammary artery. After 6 days of stretch 
(lower) the cell number was increased in the vein but not in the 
artery. From Preded et al57 with permission. 
coronary bypass grafts. As shear forces stimulate the 
release of nitric oxide and prostacyclin from the endo-
thelium, it is possible that the growth responses of vas-
cular smooth muscle cells are modulated by or inhib-
ited in the presence of endothelial cells. 
ENDOTHELIAL DYSFUNCTION 
Because of its strategic anatomic position between the 
circulating blood and vascular smooth muscle, the en-
dothelium is a primary target organ for cardiovascular 
risk factors and mechanical forces, such as pressure 
and shear stress, particularly at branching sites where 
blood flow is nonlaminar.1 
Aging Aging is one of the most important determi-
nants of vascular disease. In the rat, aging is associated 
with an increased formation of the EDCF (prosta-
glandin H 2 ) , 5 8 as well as a mild decrease in the release 
of EDRF. 5 9 In contrast, the responsiveness of vascular 
smooth muscle to nitric-oxide-forming compounds 
does not change under these conditions.5 8 In the 
human coronary microcirculation, the increase in cor-
onary flow induced by intraarterial infusions of ace-
tylcholine declines with aging. 6 0 
Endothelial Regeneration After mechanical denu-
dation of the porcine coronary artery, the capacity of 
regenerated endothelial cells to release EDNO in re-
sponse to platelet-derived serotonin is impaired be-
cause of a defect of the G{ protein linked to the endo-
thelial 5HT1-serotonergic receptor. 6 1 These functional 
alterations occurring during regeneration may con-
tribute to the age-dependent impairments of endothe-
lial function in the coronary circulation and may also 
play a role after percutaneous transluminal coronary 
angioplasty. Dysfunction of the endothelium, particu-
larly in response to platelet-derived products, may in-
crease platelet adhesion, thereby providing high local 
concentrations of platelet-derived growth factor and 
contributing to the proliferative response at sites of en-
dothelial dysfunction. 
Lipoproteins and Hypercholesterolemia Morpho-
logically, the endothelium remains intact during the 
early stages of atherogenesis; functionally, however, 
pronounced alterations occur.1 Particularly, oxidized 
low-density lipoprotein (OX-LDL) is present in human 
atherosclerotic lesions.6 2 In the porcine coronary ar-
tery, OX-LDL inhibits endotheUum-dependent relaxa-
tions to platelets, serotonin, and thrombin. 6 3 In con-
trast, relaxations to the nitric oxide donor SIN-1 are 
well maintained, excluding a reduced responsiveness 
of vascular smooth muscle to EDNO. The inhibition is 
specific for OX-LDL, as it is not induced by compara-
ble concentrations of native LDL. In the rabbit aorta 
the effect of OX-LDL is mimicked by lysolecithin (a 
characteristic component of OX-LDL). 6 4 ' 6 5 
OX-LDL appears to activate an endothelial receptor 
distinct from the LDL receptor, such as the scavenger 
receptor (Figure 8 ) 6 3 ' 6 5 ; indeed, dextran sulfate, a com-
petitive antagonist of modified LDL at this receptor, 
prevents the endothelial effects of OX-LDL. 6 3 Because 
endotheUum-dependent relaxations to serotonin, but 
not to bradykinin, are inhibited by the lipoproteins, 
they specifically interfere with endothelial production 
of nitric oxide, whereas that of other EDRFs does not 
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Vascular smooth muscle cell 
FIGURE 8. Schematic representation of the effects of oxidized low-density lipoprotein (Ox-LDL) on the endothelial L-arginine pathway 
in the coronary circulation: Ox-LDL activates the endothelial scavenger receptor and interferes with the intracellular availability of 
L-arginine (L-ARG). This reduces the efficacy of the receptor-operated activation of the L-arginine pathway by serotonin (5-HT) and other 
mediators, and thus favors vascular contraction and platelet aggregation. Modified from Tanner et al65 with permission. 
seem to be affected. Nitric oxide synthetase remains 
unaffected, however, as L-arginine evokes a full relaxa-
tion in vessels treated with OX-LDL. Because pretreat-
ment with L-arginine restores the response to sero-
tonin in vessels treated with OX-LDL, it may be that 
OX-LDL interacts with the intracellular availability of 
L-arginine (Figure 8 ) . 6 3 ' 6 5 
This mechanism may also occur in vivo, as a similar 
inhibition of endothelium-dependent relaxation to se-
rotonin and to bradykinin occurs in hypercholesterol-
emic pigs as in coronary arteries exposed to OX-LDL. 6 6 
In humans with hypercholesterolemia, L-arginine infu-
sion augments the blunted increase in coronary blood 
flow in response to acetylcholine6 7; in contrast, the loss 
of endotheUum-dependent vasodilation to ace-
tylcholine in epicardial coronary arteries is unaffected 
by the amino acid, possibly because of the presence of 
fully developed atherosclerosis. 
In addition to their effect on the L-arginine pathway, 
both native and OX-LDL inactivate nitric oxide. 6 8 OX-
LDL not only inhibits endothelium-dependent relaxa-
tion, but also causes endothelium-dependent contrac-
tion.69 In the rabbit femoral artery, OX-LDL potenti-
ates contractions to potassium chloride as well as to 
receptor-operated vasoconstrictors.7 0 
OX-LDL also induces the expression of messenger 
RNA for endothelin in cultured aortic endothelial cells 
as well as the release of the peptide from the intact por-
cine aorta (Figure 8 ) . 7 1 In this context it is of interest 
that threshold and low concentrations of endothelin, 
which by themselves evoke no appreciable vascular ef-
fect, potentiate contractions induced by serotonin in 
the human coronary artery and by norepinephrine 
and serotonin in the human internal mammary ar-
tery. 7 2 Thus, OX-LDL inhibits endotheUum-dependent 
relaxations and promotes endotheUum-dependent as 
well as endothelium-independent contractions; the 
consequences are alterations in vascular tone leading 
to vasospasm and thrombus formation, both common 
events in patients with coronary artery disease. 
Hypertension Hypertension is associated with 
morphological and functional alterations of the endo-
thelium.1 In hypertensive blood vessels, endotheUal 
cells have an increased volume, bulging into the 
lumen, and fibrin and ceU deposition is increased in 
the subintimal space. Furthermore, the interaction of 
platelets and monocytes with the endothelium is in-
creased in hypertensive vessels compared with 
normotensive controls. 
Endothelium-dependent relaxations to ace-
tylcholine are reduced in the aortic, cerebral, and pe-
ripheral microcirculations of hypertensive rats . 7 3 , 7 4 
Similarly, the vasodilator effects of acetylcholine in the 
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FIGURE 9. Effects of intraarterially infused acetylcholine on 
forearm vascular resistance in normotensive subjects (open bars) 
and patients with essential hypertension (hatched bars). Note the 
reduced effects of acetylcholine in the hypertensive patients, n.s., 
not significant; * Ρ < .05 From hinder et al4 with permission. 
human forearm of hypertensive subjects is blunted 
(Figure 9) . 4 In the spontaneously hypertensive rat, the 
reduced response to acetylcholine is related to the pro­
duction of EDCF (ie, prostaglandin H 2 ) , whereas in 
most other forms of experimentally induced hyperten­
sion a reduced formation of EDNO predominates. 7 4 In 
the mesenteric microcirculation, intraluminal (but not 
extraluminal) activation of the endothelium is dys­
functional, indicating a predominant alteration of that 
surface of the endothelium most exposed to high 
blood pressure. 7 4 
In contrast, the coronary circulation—at least as 
judged from work with the spontaneously hyperten­
sive rat model—appears less prone to hypertensive en­
dothelial dysfunction. Indeed, in epicardial coronary 
arteries of these rats, aging and hypertension only 
minimally reduce the response to acetylcholine,7 5 sug­
gesting that in the absence of hyperlipidemia, hyper­
tension exerts only a mild effect on the coronary endo­
thelium. 
Atherosclerosis In porcine coronary arteries, endo­
thelium-dependent relaxations are severely impaired 
to serotonin and also reduced to bradykinin by estab­
lished atherosclerosis.6 6 Endothelium-independent re­
laxations to nitrovasodilators remain preserved, how­
ever, except in severely atherosclerotic arteries.1 
In human coronary arteries, atherosclerosis attenu­
ates endothelium-dependent relaxations to substance 
P, bradykinin, aggregating platelets, and calcium iono-
phore, 7 6 ' 7 7 and in vivo acetylcholine and serotonin 
cause paradoxical vasoconstriction. 7 8 , 7 9 
The nature of the mechanism responsible for the 
marked impairment or loss of endothelium-dependent 
relaxations in atherosclerosis is controversial. The re­
lease of EDRF clearly is reduced in porcine coronary 
arteries with hypercholesterolemia and atherosclero­
sis. 6 6 Direct measurements of nitric oxide in the rabbit 
aorta, however, suggest an increased formation of ni­
tric oxide with a concomitant massive breakdown of 
the endogenous nitrovasodilator.8 0 The latter observa­
tion suggests that atherosclerosis is associated with in­
creased formation of superoxide radicals and other 
products inactivating nitric oxide or with decreased 
activity of superoxide dismutase in the blood vessel 
wall, or both. It is conceivable that during the more de­
veloped stages of atherosclerosis, the marked invasion 
of monocytes and other blood cells induces nitric oxide 
synthase in the subintimal space and vascular smooth 
muscle cells. However, it is not known whether altera­
tions similar to those in the rabbit aorta occur in 
human coronary arteries. 
Coronary Bypass Grafts In patients with coronary 
artery disease, surgical therapy involves implantation 
of an arterial or venous bypass graft using the internal 
mammary, gastroepiploic artery, or saphenous vein. 
The mammary artery has a remarkably higher patency 
rate than the saphenous vein. 8 1 Endothelium-derived 
vasoactive factors may be important to graft function 
as they determine the antithrombotic properties and 
the regulation of blood flow. In addition, these factors 
may have antiproliferative and proliferative proper­
ties determining the late changes occurring in coro­
nary bypass grafts. 
The mammary artery exhibits much more pro­
nounced endothelium-dependent relaxations than 
does the saphenous vein, because the release of EDNO 
by receptor-operated agonists and, in particular, by 
aggregating platelets is more efficient in the artery 
than in the vein. 8 2 , 8 3 Particularly, the release of EDNO 
in response to platelet-derived adenosine diphosphate 
is an important antithrombotic property. The gas­
troepiploic artery releases amounts of EDNO compa­
rable with those released by the mammary artery, but 
exhibits more pronounced contractions.8 4 These differ­
ences in endothelial and vascular smooth muscle func­
tions of bypass graft vessels (Figures 6, 7) may play an 
important role in graft function and patency, and, 
hence, in the survival of patients undergoing coronary 
bypass surgery. 
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